Parikh Kavita, Hall Matt, Mittal Vineeta, Montalbano Amanda, Gold Jessica, Mahant Sanjay, Wilson Karen M, Shah Samir S
Division of Hospital Medicine, Department of Pediatrics, Children's National Medical Center and George Washington School of Medicine, Washington, DC.
Children's Hospital Association, Overland Park, KS.
J Pediatr. 2015 Sep;167(3):639-44.e1. doi: 10.1016/j.jpeds.2015.06.038.
To study the comparative effectiveness of dexamethasone vs prednisone/prednisolone in children hospitalized with asthma exacerbation not requiring intensive care.
This multicenter retrospective cohort study, using the Pediatric Health Information System, included children aged 4-17 years who were hospitalized with a principal diagnosis of asthma between January 1, 2007 and December 31, 2012. Children with chronic complex condition and/or initial intensive care unit (ICU) management were excluded. Propensity score matching was used to detect differences in length of stay (LOS), readmissions, ICU transfer, and cost between groups.
40,257 hospitalizations met inclusion criteria; 1166 (2.9%) received only dexamethasone. In the matched cohort (N = 1284 representing 34 hospitals), the LOS was significantly shorter in the dexamethasone group compared with the prednisone/prednisolone group. The proportion of subjects with a LOS of 3 days or more was 6.7% in the dexamethasone group and 12% in the prednisone/prednisolone group (P = .002). Differences in all-cause readmission at 7- and 30 days were not statistically significant. The dexamethasone group had lower costs of index admission ($2621 vs $2838; P < .001) and total episode of care (including readmissions) ($2624 vs $2856; P < .001) compared with the prednisone/prednisolone group. There were no clinical significant differences in ICU transfer or readmissions between groups.
Dexamethasone may be considered an alternative to prednisone/prednisolone for children hospitalized with asthma exacerbation not requiring admission to intensive care.
研究地塞米松与泼尼松/泼尼松龙对无需重症监护的哮喘急性发作住院儿童的相对疗效。
这项多中心回顾性队列研究使用儿科健康信息系统,纳入了2007年1月1日至2012年12月31日期间因哮喘为主诊断而住院的4至17岁儿童。排除患有慢性复杂疾病和/或最初在重症监护病房(ICU)接受治疗的儿童。采用倾向评分匹配法检测两组之间住院时间(LOS)、再入院率、ICU转科率和费用的差异。
40257例住院病例符合纳入标准;1166例(2.9%)仅接受地塞米松治疗。在匹配队列(N = 1284,代表34家医院)中,地塞米松组的住院时间显著短于泼尼松/泼尼松龙组。住院时间为3天或更长时间的受试者比例在地塞米松组为6.7%,在泼尼松/泼尼松龙组为12%(P = 0.002)。7天和30天全因再入院率的差异无统计学意义。与泼尼松/泼尼松龙组相比,地塞米松组的首次住院费用较低(2621美元对2838美元;P < 0.001),总治疗费用(包括再入院)也较低(2624美元对2856美元;P < 0.001)。两组之间在ICU转科率或再入院率方面无临床显著差异。
对于因哮喘急性发作住院且无需入住重症监护的儿童,地塞米松可被视为泼尼松/泼尼松龙的替代药物。